
2003- 2006  Pfizer Pharmaceuticals Israel Ltd. Quality of life outcomes with antipsychotic treatment of schizophrenia patients: a one year prospective naturalistic comparative study of ziprasidone with atypical and typical antipsychotic agents. PI – M. Ritsner

2005 - 2006  *Stanley Foundation* (USA; grant # 05T-648). Safety and efficacy of add-on oral of add-on oral bexarotene to antipsychotic treatment in schizophrenia patients: an open label. PI - V. Lerner, Co-PI - M. Ritsner.

2006 - 2008  *Stanley Foundation* (USA; grant #06TGF-911). The value of augmenting L-Theanine in the management of schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. PI - M. Ritsner.

2007-  *Stanley Foundation* (USA; grant #07TGF-1097). Bexarotene as addition to antipsychotic treatment in schizophrenia patients: double-blind placebo controlled study. PI - V. Lerner, Co-PI - M. Ritsner.


**Publications (2005-2011):**


26. Ritsner MS, Strous RD. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J Psychiatr Res. 2010;44(2):75-80.


Books


Book chapters


